APO RESEARCH · REPORT
Microbial Fermentation APIs
Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. They are generally manufactured through a variety of processes that include chemical synthesis, fermentation processes, recombinant DNA, etc.
Product & engineering
Understand the product.
Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. They are generally manufactured through a variety of processes that include chemical synthesis, fermentation processes, recombinant DNA, etc.
Microbial fermentation APIs are secondary metabolites produced by micro-organisms such as fungi and actinomycetes. The micro-organisms are capable of converting inexpensive carbon sources (starch, glucose, sucrose, etc.) and nitrogen sources (soybean flour, cotton-seed flour, peptone, etc.) into highly valuable API's or key intermediates (such as amino acids, vitamines, antibiotics) in liquid or solid media under certain growth conditions (nutrients, temperature, PH, oxygen supply).
Microorganisms that are typically used within the pharmaceutical industry include: prokaryotes such as Bacteria (e.g. Escherichia coli, Staphylococcus aureus) and Streptomycetes (e.g. Streptomyces spp, Actinomyces spp), eukaryotes such as Filamentous Fungi (e.g., Nigrospora spp, Aspergillus spp,) and Yeast (e.g. Saccharomyces cereviciae, Pichia pastoris).
Selected research
Industry Research
Microbial Fermentation APIs Industry Research Report 2026
Market perspective
Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. They are generally manufactured through a variety of processes that include chemical synthesis, fermentation processes, recombinant DNA, etc.
Microbial fermentation APIs are secondary metabolites produced by micro-organisms such as fungi and actinomycetes. The micro-organisms are capable of converting inexpensive carbon sources (starch, glucose, sucrose, etc.) and nitrogen sources (soybean flour, cotton-seed flour, peptone, etc.) into highly valuable API's or key intermediates (such as amino acids, vitamines, antibiotics) in liquid or solid media under certain growth conditions (nutrients, temperature, PH, oxygen supply).
Microorganisms that are typically used within the pharmaceutical industry include: prokaryotes such as Bacteria (e.g. Escherichia coli, Staphylococcus aureus) and Streptomycetes (e.g. Streptomyces spp, Actinomyces spp), eukaryotes such as Filamentous Fungi (e.g., Nigrospora spp, Aspergillus spp,) and Yeast (e.g. Saccharomyces cereviciae, Pichia pastoris).
Read the full market overview
The major players in global Microbial Fermentation APIs market include Merck, Ajinomoto, HGPF, etc. China is the main market, and occupies about 50% of the global market. Antibiotics and Amino Acids are main types, with a share over 60%.
Report Scope
This report quantifies the global Microbial Fermentation APIs market in terms of revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Microbial Fermentation APIs Market by Company
Merck
Ajinomoto
HGPF
Huaxing
North China Pharmaceutical
Topfond
DSM
Tianyao
CSPC Pharma
Northeast Pharm
Lukang Pharmaceutical
Luwei Pharmaceutical
Jiangshan (DSM)
Microbial Fermentation APIs Segment by Type
Antibiotics
Amino Acids
Vitamin
Nucleotide
Organic Acid
Alcohol
Biological Products
Hormone
Microbial Fermentation APIs Segment by Application
Hospitals
Research & Academic Laboratories
Pharmaceutical & Biotechnology Companies
Microbial Fermentation APIs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbial Fermentation APIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbial Fermentation APIs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbial Fermentation APIs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Microbial Fermentation APIs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Microbial Fermentation APIs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Microbial Fermentation APIs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antibiotics
- Amino Acids
- Vitamin
- Nucleotide
- Organic Acid
- Alcohol
- Biological Products
- Hormone
Applications
- Hospitals
- Research & Academic Laboratories
- Pharmaceutical & Biotechnology Companies
Companies covered
- Merck
- Ajinomoto
- HGPF
- Huaxing
- North China Pharmaceutical
- Topfond
- DSM
- Tianyao
- CSPC Pharma
- Northeast Pharm
- Lukang Pharmaceutical
- Luwei Pharmaceutical
- Jiangshan (DSM)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Microbial Fermentation APIs Market Size (2021-2032)
- 2.2.2 Global Microbial Fermentation APIs Sales (2021-2032)
- 2.2.3 Global Microbial Fermentation APIs Market Average Price (2021-2032)
- 2.3 Microbial Fermentation APIs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Antibiotics
- 2.3.3 Amino Acids
- 2.3.4 Vitamin
- 2.3.5 Nucleotide
- 2.3.6 Organic Acid
- 2.3.7 Alcohol
- 2.3.8 Biological Products
- 2.3.9 Hormone
- 2.4 Microbial Fermentation APIs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Research & Academic Laboratories
- 2.4.4 Pharmaceutical & Biotechnology Companies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Microbial Fermentation APIs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Microbial Fermentation APIs Sales (t) of Manufacturers (2021-2026)
- 3.3 Global Microbial Fermentation APIs Revenue of Manufacturers (2021-2026)
- 3.4 Global Microbial Fermentation APIs Average Price by Manufacturers (2021-2026)
- 3.5 Global Microbial Fermentation APIs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Microbial Fermentation APIs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Microbial Fermentation APIs, Product Type & Application
- 3.8 Global Manufacturers of Microbial Fermentation APIs, Established Date
- 3.9 Global Microbial Fermentation APIs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Microbial Fermentation APIs Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 Ajinomoto
- 4.2.1 Ajinomoto Company Information
- 4.2.2 Ajinomoto Business Overview
- 4.2.3 Ajinomoto Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Ajinomoto Microbial Fermentation APIs Product Portfolio
- 4.2.5 Ajinomoto Recent Developments
- 4.3 HGPF
- 4.3.1 HGPF Company Information
- 4.3.2 HGPF Business Overview
- 4.3.3 HGPF Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 HGPF Microbial Fermentation APIs Product Portfolio
- 4.3.5 HGPF Recent Developments
- 4.4 Huaxing
- 4.4.1 Huaxing Company Information
- 4.4.2 Huaxing Business Overview
- 4.4.3 Huaxing Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Huaxing Microbial Fermentation APIs Product Portfolio
- 4.4.5 Huaxing Recent Developments
- 4.5 North China Pharmaceutical
- 4.5.1 North China Pharmaceutical Company Information
- 4.5.2 North China Pharmaceutical Business Overview
- 4.5.3 North China Pharmaceutical Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 North China Pharmaceutical Microbial Fermentation APIs Product Portfolio
- 4.5.5 North China Pharmaceutical Recent Developments
- 4.6 Topfond
- 4.6.1 Topfond Company Information
- 4.6.2 Topfond Business Overview
- 4.6.3 Topfond Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Topfond Microbial Fermentation APIs Product Portfolio
- 4.6.5 Topfond Recent Developments
- 4.7 DSM
- 4.7.1 DSM Company Information
- 4.7.2 DSM Business Overview
- 4.7.3 DSM Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 DSM Microbial Fermentation APIs Product Portfolio
- 4.7.5 DSM Recent Developments
- 4.8 Tianyao
- 4.8.1 Tianyao Company Information
- 4.8.2 Tianyao Business Overview
- 4.8.3 Tianyao Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Tianyao Microbial Fermentation APIs Product Portfolio
- 4.8.5 Tianyao Recent Developments
- 4.9 CSPC Pharma
- 4.9.1 CSPC Pharma Company Information
- 4.9.2 CSPC Pharma Business Overview
- 4.9.3 CSPC Pharma Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CSPC Pharma Microbial Fermentation APIs Product Portfolio
- 4.9.5 CSPC Pharma Recent Developments
- 4.10 Northeast Pharm
- 4.10.1 Northeast Pharm Company Information
- 4.10.2 Northeast Pharm Business Overview
- 4.10.3 Northeast Pharm Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Northeast Pharm Microbial Fermentation APIs Product Portfolio
- 4.10.5 Northeast Pharm Recent Developments
- 4.11 Lukang Pharmaceutical
- 4.11.1 Lukang Pharmaceutical Company Information
- 4.11.2 Lukang Pharmaceutical Business Overview
- 4.11.3 Lukang Pharmaceutical Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Lukang Pharmaceutical Microbial Fermentation APIs Product Portfolio
- 4.11.5 Lukang Pharmaceutical Recent Developments
- 4.12 Luwei Pharmaceutical
- 4.12.1 Luwei Pharmaceutical Company Information
- 4.12.2 Luwei Pharmaceutical Business Overview
- 4.12.3 Luwei Pharmaceutical Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Luwei Pharmaceutical Microbial Fermentation APIs Product Portfolio
- 4.12.5 Luwei Pharmaceutical Recent Developments
- 4.13 Jiangshan (DSM)
- 4.13.1 Jiangshan (DSM) Company Information
- 4.13.2 Jiangshan (DSM) Business Overview
- 4.13.3 Jiangshan (DSM) Microbial Fermentation APIs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Jiangshan (DSM) Microbial Fermentation APIs Product Portfolio
- 4.13.5 Jiangshan (DSM) Recent Developments
5 Global Microbial Fermentation APIs Market Scenario by Region
- 5.1 Global Microbial Fermentation APIs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Microbial Fermentation APIs Sales by Region: 2021-2032
- 5.2.1 Global Microbial Fermentation APIs Sales by Region: 2021-2026
- 5.2.2 Global Microbial Fermentation APIs Sales by Region: 2027-2032
- 5.3 Global Microbial Fermentation APIs Revenue by Region: 2021-2032
- 5.3.1 Global Microbial Fermentation APIs Revenue by Region: 2021-2026
- 5.3.2 Global Microbial Fermentation APIs Revenue by Region: 2027-2032
- 5.4 North America Microbial Fermentation APIs Market Facts & Figures by Country
- 5.4.1 North America Microbial Fermentation APIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Microbial Fermentation APIs Sales by Country (2021-2032)
- 5.4.3 North America Microbial Fermentation APIs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Microbial Fermentation APIs Market Facts & Figures by Country
- 5.5.1 Europe Microbial Fermentation APIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Microbial Fermentation APIs Sales by Country (2021-2032)
- 5.5.3 Europe Microbial Fermentation APIs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Microbial Fermentation APIs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Microbial Fermentation APIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Microbial Fermentation APIs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Microbial Fermentation APIs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Microbial Fermentation APIs Market Facts & Figures by Country
- 5.7.1 South America Microbial Fermentation APIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Microbial Fermentation APIs Sales by Country (2021-2032)
- 5.7.3 South America Microbial Fermentation APIs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Microbial Fermentation APIs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Microbial Fermentation APIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Microbial Fermentation APIs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Microbial Fermentation APIs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Microbial Fermentation APIs Sales by Type (2021-2032)
- 6.1.1 Global Microbial Fermentation APIs Sales by Type (2021-2032) & (t)
- 6.1.2 Global Microbial Fermentation APIs Sales Market Share by Type (2021-2032)
- 6.2 Global Microbial Fermentation APIs Revenue by Type (2021-2032)
- 6.2.1 Global Microbial Fermentation APIs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Microbial Fermentation APIs Revenue Market Share by Type (2021-2032)
- 6.3 Global Microbial Fermentation APIs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Microbial Fermentation APIs Sales by Application (2021-2032)
- 7.1.1 Global Microbial Fermentation APIs Sales by Application (2021-2032) & (t)
- 7.1.2 Global Microbial Fermentation APIs Sales Market Share by Application (2021-2032)
- 7.2 Global Microbial Fermentation APIs Revenue by Application (2021-2032)
- 7.2.1 Global Microbial Fermentation APIs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Microbial Fermentation APIs Revenue Market Share by Application (2021-2032)
- 7.3 Global Microbial Fermentation APIs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Microbial Fermentation APIs Value Chain Analysis
- 8.1.1 Microbial Fermentation APIs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Microbial Fermentation APIs Production Mode & Process
- 8.2 Microbial Fermentation APIs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Microbial Fermentation APIs Distributors
- 8.2.3 Microbial Fermentation APIs Customers
9 Global Microbial Fermentation APIs Analyzing Market Dynamics
- 9.1 Microbial Fermentation APIs Industry Trends
- 9.2 Microbial Fermentation APIs Industry Drivers
- 9.3 Microbial Fermentation APIs Industry Opportunities and Challenges
- 9.4 Microbial Fermentation APIs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst